EyePoint Pharmaceuticals Inc (EYPT)
16.48
-1.08
(-6.18%)
USD |
NASDAQ |
Apr 24, 16:00
16.48
0.00 (0.00%)
After-Hours: 20:00
EyePoint Pharmaceuticals Enterprise Value: 544.48M for April 23, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 23, 2024 | 544.48M |
| April 22, 2024 | 513.58M |
| April 19, 2024 | 548.46M |
| April 18, 2024 | 540.99M |
| April 17, 2024 | 712.41M |
| April 16, 2024 | 757.25M |
| April 15, 2024 | 729.35M |
| April 12, 2024 | 787.65M |
| April 11, 2024 | 809.58M |
| April 10, 2024 | 750.78M |
| April 09, 2024 | 741.81M |
| April 08, 2024 | 701.94M |
| April 05, 2024 | 679.52M |
| April 04, 2024 | 673.04M |
| April 03, 2024 | 702.94M |
| April 02, 2024 | 679.52M |
| April 01, 2024 | 679.02M |
| March 28, 2024 | 698.95M |
| March 27, 2024 | 705.93M |
| March 26, 2024 | 696.96M |
| March 25, 2024 | 749.78M |
| March 22, 2024 | 778.18M |
| March 21, 2024 | 835.99M |
| March 20, 2024 | 832.50M |
| March 19, 2024 | 770.21M |
| Date | Value |
|---|---|
| March 18, 2024 | 730.35M |
| March 15, 2024 | 739.32M |
| March 14, 2024 | 752.27M |
| March 13, 2024 | 769.71M |
| March 12, 2024 | 805.59M |
| March 11, 2024 | 808.58M |
| March 08, 2024 | 884.82M |
| March 07, 2024 | 930.17M |
| March 06, 2024 | 951.59M |
| March 05, 2024 | 943.12M |
| March 04, 2024 | 960.07M |
| March 01, 2024 | 1.064B |
| February 29, 2024 | 1.003B |
| February 28, 2024 | 1.026B |
| February 27, 2024 | 1.075B |
| February 26, 2024 | 971.04M |
| February 23, 2024 | 970.80M |
| February 22, 2024 | 948.97M |
| February 21, 2024 | 974.97M |
| February 20, 2024 | 1.028B |
| February 16, 2024 | 1.057B |
| February 15, 2024 | 1.095B |
| February 14, 2024 | 1.087B |
| February 13, 2024 | 1.122B |
| February 12, 2024 | 1.126B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-36.76M
Minimum
Dec 19 2022
1.126B
Maximum
Feb 12 2024
217.39M
Average
163.65M
Median
Enterprise Value Benchmarks
| INVO Bioscience Inc | 12.10M |
| Bio-Path Holdings Inc | 0.7672M |
| Ocular Therapeutix Inc | 622.26M |
| Aileron Therapeutics Inc | 63.99M |
| Apellis Pharmaceuticals Inc | 5.617B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -14.10M |
| Revenue (Quarterly) | 14.03M |
| Total Expenses (Quarterly) | 30.38M |
| EPS Diluted (Quarterly) | -0.32 |
| Gross Profit Margin (Quarterly) | 92.89% |
| Profit Margin (Quarterly) | -100.5% |
| Earnings Yield | -11.04% |
| Normalized Earnings Yield | -10.82 |